| Rights | Preview | Issue Date | Title | Author(s) | Type |
| closedAccess |  | 2008 | Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo | Mitsiades, C. S.; Ocio, Enrique M.  ; Pandiella, Atanasio ; Maiso, Patricia; Gajate, Consuelo; Garayoa, Mercedes ; Vilanova, David; Montero, Juan Carlos ; Mollinedo, Faustino ; San Miguel, Jesús F. | artículo |
| openAccess |  | 2012 | CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype | Paíno, Teresa ; Ocio, Enrique M. ; Paiva, Bruno; San-Segundo, Laura; Garayoa, Mercedes ; Gutiérrez, Norma Carmen; Sarasquete, María Eugenia; Pandiella, Atanasio ; Orfao, Alberto ; San Miguel, Jesús F. | artículo |
| openAccess |  | 2012 | Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects | García-Gómez, Antonio; Ocio, Enrique M. ; Crusoe, Edvan; Santamaría, Carlos; Hernández-Campo, Pilar M.; Blanco, Juan F.; Sánchez-Guijo, Fermín M.; Hernández, M. Teresa ; Briñón, Jesús G.; Pandiella, Atanasio ; San Miguel, Jesús F. ; Garayoa, Mercedes | artículo |
| closedAccess |  | 2019 | Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: Potential antitumour dual agents | González-Hernández, Elena; Aparicio, Rubén; Garayoa, Mercedes ; Montero, María J.; Sevilla, Mª Ángeles; Pérez-Melero, Concepción | artículo |
| openAccess |  | 1-May-2010 | In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma | Ocio, Enrique M. ; Vilanova, David; Maiso, Patricia; Crusoe, Edvan; Fernández-Lázaro, Diego; Garayoa, Mercedes ; San-Segundo, Laura; Hernández, M. Teresa ; San Miguel, Jesús F. | artículo |
| closedAccess |  | 2015 | In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone | Ocio, Enrique M. ; Fernández-Lázaro, Diego; San-Segundo, Laura; López-Corral, L.; Corchete, Luis A.; Gutiérrez, Norma Carmen; Garayoa, Mercedes ; Paíno, Teresa ; García-Gómez, Antonio; Delgado, Manuel; Montero, Juan Carlos ; Díaz-Rodríguez, Elena ; Mateos, Maria Victoria; Pandiella, Atanasio ; San Miguel, Jesús F. | artículo |
| closedAccess |  | 2009 | Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donorsGenomic profile of multiple myeloma MSCs | Garayoa, Mercedes ; García, Juan L. ; Santamaría, Carlos; García-Gómez, Antonio; Blanco, Juan F.; Pandiella, Atanasio ; Hernández, Jesús M. ; Sánchez-Guijo, Fermín M.; Cañizo, María Consuelo del; Gutiérrez, Norma Carmen; San Miguel, Jesús F. | artículo |
| openAccess |  | 2014 | Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines | Paíno, Teresa ; Sarasquete, María Eugenia; Paiva, Bruno; Krzemiński, Patryk; San-Segundo, Laura; Corchete, Luis A.; Redondo, Alba; Garayoa, Mercedes ; García-Sanz, Ramón; Gutiérrez, Norma Carmen; Ocio, Enrique M. ; San Miguel, Jesús F. | artículo |
| closedAccess |  | 2014 | Preclinical activity of the oral proteasome inhibitor mln9708 in myeloma bone disease | García-Gómez, Antonio; Ocio, Enrique M. ; Blanco, Juan F.; Hernández-Iglesias, Teresa; Fraile, Susana ; San Miguel, Jesús F. ; Garayoa, Mercedes | artículo |
| openAccess |  | 2017 | Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair | López-Iglesias, Ana-Alicia; Herrero, Ana B.; Chesi, Marta; San-Segundo, Laura; González-Méndez, Lorena; Hernández-García, Susana; Misiewicz-Krzeminska, Irena; Quwaider, Dalia; Martín-Sánchez, Montserrat; Primo, Daniel; Paíno, Teresa ; Bergsagel, P. Leif; Mehrling, Thomas; González, Marcos ; San Miguel, Jesús F. ; Mateos, Maria Victoria; Gutiérrez, Norma Carmen; Garayoa, Mercedes ; Ocio, Enrique M. | artículo |
| closedAccess |  | 2013 | RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications | García-Gómez, Antonio; Ocio, Enrique M. ; Pandiella, Atanasio ; San Miguel, Jesús F. ; Garayoa, Mercedes | artículo |
| openAccess |  | Feb-2013 | Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function | García-Bernal, David ; Redondo-Muñoz, Javier; Dios-Esponera, Ana ; Chèvre, Raphaël; Bailón, Elvira ; Garayoa, Mercedes ; Arellano-Sánchez, Nohemí ; Gutiérrez, Norma C.; Hidalgo, Andrés; García-Pardo, Angeles ; Teixidó, Joaquín | artículo |
| openAccess |  | 2017 | Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone | López-Iglesias, Ana-Alicia; González-Méndez, Lorena; San-Segundo, Laura; Herrero, Ana B.; Hernández-García, Susana; Martín-Sánchez, Montserrat; Gutiérrez, Norma Carmen; Paíno, Teresa ; Avilés Marín, Pablo; Mateos, Maria Victoria; San Miguel, Jesús F. ; Garayoa, Mercedes ; Ocio, Enrique M. | artículo |
| openAccess |  | 2008 | The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype | Colado, Enrique; Álvarez-Fernández, Stela ; Maiso, Patricia; Martín, Jesús; Vidriales, Maria Belén; Garayoa, Mercedes ; Ocio, Enrique M. ; Montero, Juan Carlos ; Pandiella, Atanasio ; San Miguel, Jesús F. | artículo |
| openAccess |  | 2013 | The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects | García-Gómez, Antonio; Ocio, Enrique M. ; Blanco, Juan F.; Pandiella, Atanasio ; San Miguel, Jesús F. ; Garayoa, Mercedes ; Weilbaecher, K. N. | artículo |
| closedAccess |  | 2008 | The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells | Maiso, Patricia; Ocio, Enrique M. ; Garayoa, Mercedes ; Montero, Juan Carlos ; Pandiella, Atanasio ; San Miguel, Jesús F. | artículo |
| openAccess |  | 2017 | The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care | Paíno, Teresa ; García-Gómez, Antonio; González-Méndez, Lorena; San-Segundo, Laura; Hernández-García, Susana; López-Iglesias, Ana-Alicia; Algarín, Esperanza M.; Martín-Sánchez, Montserrat; Corbacho-González, David; Ortiz-de-Solorzano, Carlos; Corchete, Luis A.; Gutiérrez, Norma Carmen; Mateos, Maria Victoria; Garayoa, Mercedes ; Ocio, Enrique M. | artículo |
| closedAccess |  | 2009 | The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repairSynergy of panobinostat and doxorubicin in AML | Maiso, Patricia; Colado, Enrique; Ocio, Enrique M. ; Garayoa, Mercedes ; Pandiella, Atanasio ; San Miguel, Jesús F. | artículo |
| openAccess |  | 2014 | Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease | García-Gómez, Antonio; De Las Rivas, Javier ; Ocio, Enrique M. ; Díaz-Rodríguez, Elena ; Montero, Juan Carlos ; Martín-Sánchez, Montserrat; Blanco, Juan F.; Sánchez-Guijo, Fermín M.; Pandiella, Atanasio ; San Miguel, Jesús F. ; Garayoa, Mercedes | artículo |
| closedAccess |  | 2012 | Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma | Queiroz Crusoe, Edvan de; Maiso, Patricia; Fernández-Lázaro, Diego; San-Segundo, Laura; Garayoa, Mercedes ; García-Gómez, Antonio; Gutiérrez, Norma Carmen; Delgado, Manuel; Colado, Enrique; Ocio, Enrique M. | artículo |
